Treatment of patients with Schistosomiasis mansoni: a double blind clinical trial comparing praziquantel with oxamniquine

Author:

Silva Luiz Caetano da1,Zeitune José Murilo R.1,Rosa-Eid Lucia Maria F.2,Lima Dirce Mary C.1,Antonelli Rita H.1,Christo Carlos H.1,Saez-Alquezar Amadeo3,Carboni Adriany de Castro3

Affiliation:

1. Instituto de Medicina Tropical de São Paulo, Brasil

2. Inst. Med. Tropical S. Paulo

3. U.S.P.

Abstract

A double-blind clinical trial involving 120 patients with chronic schistosomiasis was carried out to compare the tolerability and efficacy of praziquantel and oxamniquine. The patients were randomly allocated into two groups. One was treated with praziquantel, 55 mg/kg of body weight CBWT), and the other one with oxamniquine, 15mg/kg bwt, administered in a single oral dose. The diagnosis and the parasitological follow-up was based on stool examinations by quantitative Kato-Katz method and on rectal biopsies. Side-effects — mainly dizziness, sleepness, abdominal distress, headache, nausea and diarrhea — were observed in 87% of the cases. Their incidence, intensity and duration were similar for both drugs but abdominal pain was significantly more frequent after praziquantel intake and severe dizziness was more commonly reported after oxamniquine. A significant increase of alanine-aminotransferase and y-glutamyltransferase was found with the latter drug and of total bilirubin with the former one. A total of 48 patients treated with praziquantel and 46 with oxamniquine completed with negative findings the required three post-treatment parasitological controls — three slides of each stool sample on the first, third and sixth month. The achieved cure rates were 79.2% and 84.8%, respectively, a difference without statistical significance. The non-cured cases showed a mean reduction in the number of eggs per gram of feces of 93.5% after praziquantel and of 84.1% after oxamniquine. This diference also was not significant. Five patients retreated with praziquantel were cured but only one out of three treated a second time with oxamniquine. These findings show that both drugs — despite their different chemical structures, pharmacological properties and mechanisms-of-action — induce similar side-effects as well as a comparable therapeutical efficacy, in agreement with the results reported from analogous investigations.

Publisher

FapUNIFESP (SciELO)

Subject

Infectious Diseases,General Medicine

Reference32 articles.

1. Susceptibility to chemoterapeutic agents of strains of Schistosoma mansoni isolated from treated and untreated patients;ARAUJO N.;Amer. J. trop. Med. Hyg.,1980

2. Convulsão associada ao uso da oxaminiquine: Relato de um caso;BINA J. C.;Rev. Soc. bras. Med. trop.,1976

3. Double-blind clinical trial comparing praziquantel with oxamniquine in the treatment of patients with schistosomiasis mansoni;BRANCHINI M. L. M.;Rev. Inst. Med. trop. S. Paulo,1982

4. Experiência com hycanthone em 3.100 portadores de esquistossomose mansônica;BUAIS V.;Rev. Ass. med. bras.,1976

5. Hycanthone resistance in a human strain of Schistosoma mansoni;CAMPOS R.;Trans, roy. Soc. trop. Med. Hyg.,1973

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3